Summit Therapeutics PLC (SMMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Summit Therapeutics PLC (SMMT) has a cash flow conversion efficiency ratio of -0.266x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-167.78 Million) by net assets ($629.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Summit Therapeutics PLC stock valuation for the company's overall valuation and market capitalisation.
Summit Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Summit Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Summit Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Summit Therapeutics PLC ranked by their cash flow conversion efficiency. Explore SMMT operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Euronext N.V.
PA:ENX
|
0.018x |
|
KUAISHOU TECHNOLOGY CL.B
F:5Y0
|
N/A |
|
Pershing Square Inc.
NYSE:PS
|
0.099x |
|
Harmony Gold Mining Company Ltd
BA:HMY
|
0.075x |
|
REA Group Limited
F:R9C
|
0.068x |
|
Coca-Cola Consolidated Inc.
NASDAQ:COKE
|
-0.283x |
|
Fox Corp Class A
NASDAQ:FOXA
|
-0.010x |
|
Yunnan Aluminium Co Ltd
SHE:000807
|
0.090x |
Annual Cash Flow Conversion Efficiency for Summit Therapeutics PLC (2003–2025)
The table below shows the annual cash flow conversion efficiency of Summit Therapeutics PLC from 2003 to 2025. View SMMT share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $488.98 Million | $-239.67 Million | -0.490x | -34.08% |
| 2024-12-31 | $310.64 Million | $-113.56 Million | -0.366x | +63.00% |
| 2023-12-31 | $61.48 Million | $-60.74 Million | -0.988x | -200.93% |
| 2022-12-31 | $103.25 Million | $-33.90 Million | -0.328x | +62.33% |
| 2021-12-31 | $61.74 Million | $-53.81 Million | -0.872x | -43.93% |
| 2020-12-31 | $58.36 Million | $-35.34 Million | -0.606x | -38.80% |
| 2019-12-31 | $61.12 Million | $-26.66 Million | -0.436x | +30.67% |
| 2018-12-31 | $55.79 Million | $-35.11 Million | -0.629x | +57.26% |
| 2017-12-31 | $13.98 Million | $-20.58 Million | -1.472x | +57.64% |
| 2016-12-31 | $-4.37 Million | $15.18 Million | -3.476x | -327.51% |
| 2015-12-31 | $30.10 Million | $-24.47 Million | -0.813x | +4.27% |
| 2014-12-31 | $19.53 Million | $-16.59 Million | -0.849x | +31.09% |
| 2013-12-31 | $7.85 Million | $-9.68 Million | -1.232x | -10.25% |
| 2012-12-31 | $4.50 Million | $-5.03 Million | -1.118x | -11.09% |
| 2011-12-31 | $3.78 Million | $-3.80 Million | -1.006x | -35.07% |
| 2010-12-31 | $5.82 Million | $-4.34 Million | -0.745x | -272.40% |
| 2009-12-31 | $13.22 Million | $-2.65 Million | -0.200x | +83.25% |
| 2008-12-31 | $12.33 Million | $-14.72 Million | -1.194x | -300.46% |
| 2007-12-31 | $54.08 Million | $-16.13 Million | -0.298x | -100.73% |
| 2006-12-31 | $40.11 Million | $-5.96 Million | -0.149x | -272.67% |
| 2005-12-31 | $23.38 Million | $-931.84K | -0.040x | -3655.45% |
| 2004-12-31 | $26.53 Million | $29.74K | 0.001x | +100.25% |
| 2003-12-31 | $142.31K | $-64.97K | -0.457x | -- |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cance… Read more